Print Friendly, PDF & Email

NCT/Study#

NA /

BST004

A Phase 2, Open Label, Single Arm, Multi‐Center Study To Assess The Efficacy And Safety Of BST‐236 As A Single Agent In Adults Unfit For Intensive Chemotherapy With Relapsed Or Refractory Acute Myeloid Leukemia Or Higher-Risk Myelodysplastic Syndrome?

DISEASE GROUP:
Leukemia
current phase:
Phase II
STUDY STATUS:
Active
Location:
Hackensack, NJ
For More information: